<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04010955</url>
  </required_header>
  <id_info>
    <org_study_id>Add-on_001</org_study_id>
    <nct_id>NCT04010955</nct_id>
  </id_info>
  <brief_title>Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)</brief_title>
  <acronym>(ADD-ON)</acronym>
  <official_title>The Role of Additional Antiplatelet Therapy in the Ischemic Stroke With Atrial Fibrillation and Co-morbiD Atherosclerosis During edOxaban treatmeNt. (ADD-ON) Study, Multicenter Registry-based Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ewha Womans University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonbuk National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dongtan Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eulji University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the effectiveness and safety regarding treatment with standard
      anticoagulant only or adding antiplatelet to anticoagulant in patients with non-valvular
      atrial fibrillation and significant atherosclerosis including extracranial, intracranial,
      coronary or peripheral artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although there is a significant increase in the risk of cerebral infarction in the presence
      of atrial fibrillation, it is difficult to say that all cerebral infarctions occurring in
      patients with atrial fibrillation are caused by atrial fibrillation. Carotid stenosis is
      found in 1/4 of patients with atrial fibrillation, which increases the risk of cerebral
      infarction. Additional antiplatelet therapy to standard anticoagulation therapy should be
      considered in some patients. To date, the best medical treatment for prevention of cerebral
      infarction in patients with atrial fibrillation and accompanying atherosclerosis has not been
      evaluated yet.

      Edoxaban reduced bleeding complication compared to warfarin in patients with atrial
      fibrillation. In addition, the ENGAGE AF TIMI-48 study showed a tendency to reduce cerebral
      infarction (p for interaction = 0.08) when administered in combination with one antiplatelet
      agent and edoxaban. The administration of antiplatelet agents may be due to patients had
      accompanying myocardial infarction or cerebral infarction. This group is also thought to have
      a high risk of bleeding due to high HAS-BLED scores. Nonetheless, there was a similar degree
      of bleeding in patients receiving additional antiplatelet agents. There was also less
      bleeding in the warfarin arm than in the use of additional antiplatelet agents. (Major
      bleeding: 0.19 vs 0.24% / yr; intracranial hemorrhage: 0.43 vs 0.57% / yr)

      Thus, Edoxaban have good clinical trial results in combination with antiplatelet agents in
      atrial fibrillation with atherosclerosis compared to other NOACs(new oral anticoagulants). It
      is also considered to be suitable for combination therapy with antiplatelet agents because of
      its advantages in different bleeding compared to other warfarin. However, there is no
      evidence to suggest that Edoxaban alone or in combination with additional antiplatelet agents
      is better for stroke patients with atrial fibrillation and significant arteriosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>MACE (major adverse cardiac event)</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for first occurrence of major cardiovascular events after patient registration: ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic stroke</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for first occurrence of hemorrhagic stroke after patient registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for first occurrence of stroke (ischemic and hemorrhagic) after patient registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Myocardial Infarction</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for first occurrence of acute myocardial infarction after patient registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for occurrence of major bleeding based on ISTH( International Society on Thrombosis and Haemostasis) after patient registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular death</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for first occurrence of vascular death after patient registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>18 months</time_frame>
    <description>Duration for first occurrence of ischemic stroke after patient registration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net clinical benefit based on reduction in major adverse cardiac event compared to major bleeding events</measure>
    <time_frame>18 months</time_frame>
    <description>Net clinical benefit based on reduction in major adverse cardiac event compared to major bleeding events</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Extracranial Atherosclerosis</condition>
  <condition>Intracranial Atherosclerosis</condition>
  <condition>Coronary Artery Atherosclerosis</condition>
  <condition>Peripheral Artery Stenosis</condition>
  <condition>Anticoagulant</condition>
  <condition>Antiplatelet</condition>
  <arm_group>
    <arm_group_label>Edoxaban Monotherapy</arm_group_label>
    <description>edoxaban monotherapy without additional antiplatelet therapy in long term stroke prevention.
However, transient additional antiplatelet therapy will be allowed at the discretion of duty physicians.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edoxaban and antiplatelet combination</arm_group_label>
    <description>edoxaban plus additional antiplatelet therapy in long term stroke prevention. However, transient cessation of antiplatelet therapy will be allowed at the discretion of duty physicians.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban Monotherapy</intervention_name>
    <description>when the patients will be initially registered in this study, duty physicians will make a decision to give additional antiplatelet therapy in addition to standard edoxaban therapy.</description>
    <arm_group_label>Edoxaban Monotherapy</arm_group_label>
    <arm_group_label>Edoxaban and antiplatelet combination</arm_group_label>
    <other_name>Edoxaban and antiplatelet combination</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute cerebral infarction or transient ischemic attack with non-valvular
        atrial fibrillation and significant artherosclerosis

        Significant atherosclerosis means atherosclerosis in the cerebral, coronary or peripheral
        arteries according to the judgment of the researchers.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with acute cerebral infarction or transient ischemic attack within 14 days of
             symptom onset based on Last Known Normal Time.

          2. Patients with non-valvular atrial fibrillation including paroxysmal atrial
             fibrillation which is eligible for treatment with Edoxaban.

          3. Patients with significant atherosclerosis confirmed by imaging tests on the cerebral
             arteries, coronary arteries, or peripheral arteries and suitable for the use of
             antiplatelet agents.

               -  Significant intracranial internal stenosis confirmed by CTA or MRA

               -  A history of coronary artery disease, meaningful findings from CTA or CAG
                  Arterial stenosis

               -  Peripheral arterial disease (Ankle-Brachial Index, ABI &lt;0.9, significant stenosis
                  found in lower limb ultrasonography

        3) Men and women over 20 years old 4) Patients who voluntarily agreed to register the
        registry

        Exclusion Criteria:

          1. Patients with chronic renal failure (GFR &lt;30 ml / min) or severe liver damage

          2. patients requiring warfarin medication due to prosthetic valve replacement

          3. patients with internal bleeding (active internal bleeding)

          4. bleeding diathesis

          5. History of acute myocardial infarction or received coronary artery procedure within 6
             months before screening

          6. Patients who have received or are scheduled to undergo carotid stenting within 1 year

          7. Currently, two or more antiplatelet agents are required due to arteriosclerosis.

          8. Patients whose survival period is expected to be less than 12 months due to serious
             diseases such as terminal cancer or liver failure

          9. Patients who are scheduled for invasive surgery with possible uncontrolled bleeding,
             including major surgery

         10. Women who are pregnant or lactating, do not have contraception during the study

         11. A person who is found to be unsuitable for participation in the study due to the
             clinical laboratory test results or other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun U. Kwon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun U. Kwon, MD, PhD</last_name>
    <phone>82-2-3010-3960</phone>
    <email>sukwon@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun U. Kwon, MD, PhD</last_name>
      <phone>82-2-3010-3960</phone>
      <email>sukwon@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010 Jul;123(7):638-645.e4. doi: 10.1016/j.amjmed.2009.11.025. Review.</citation>
    <PMID>20609686</PMID>
  </reference>
  <reference>
    <citation>Willeit K, Pechlaner R, Egger G, Weger S, Oberhollenzer M, Willeit J, Kiechl S. Carotid atherosclerosis and incident atrial fibrillation. Arterioscler Thromb Vasc Biol. 2013 Nov;33(11):2660-5. doi: 10.1161/ATVBAHA.113.302272. Epub 2013 Sep 12.</citation>
    <PMID>24030550</PMID>
  </reference>
  <reference>
    <citation>Kanter MC, Tegeler CH, Pearce LA, Weinberger J, Feinberg WM, Anderson DC, Gomez CR, Rothrock JF, Helgason CM, Hart RG. Carotid stenosis in patients with atrial fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. Arch Intern Med. 1994 Jun 27;154(12):1372-7.</citation>
    <PMID>8002689</PMID>
  </reference>
  <reference>
    <citation>Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002;13(1):16-20.</citation>
    <PMID>11810005</PMID>
  </reference>
  <reference>
    <citation>Lehtola H, Airaksinen KEJ, Hartikainen P, Hartikainen JEK, Palomäki A, Nuotio I, Ylitalo A, Kiviniemi T, Mustonen P. Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk. Eur J Neurol. 2017 May;24(5):719-725. doi: 10.1111/ene.13280. Epub 2017 Mar 20.</citation>
    <PMID>28317289</PMID>
  </reference>
  <reference>
    <citation>Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.</citation>
    <PMID>17577005</PMID>
  </reference>
  <reference>
    <citation>Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, Levine SR, Chaturvedi S, Kasner SE, Benesch CG, Sila CA, Jovin TG, Romano JG; Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005 Mar 31;352(13):1305-16.</citation>
    <PMID>15800226</PMID>
  </reference>
  <reference>
    <citation>Fisher M. Does the combination of warfarin and aspirin have a place in secondary stroke prevention? No. Stroke. 2009 May;40(5):1944-5. doi: 10.1161/STROKEAHA.108.537670. Epub 2009 Mar 19.</citation>
    <PMID>19299634</PMID>
  </reference>
  <reference>
    <citation>Kim BJ, Kim HJ, Do Y, Lee JH, Park KY, Cha JK, Kim HY, Kwon JH, Lee KB, Kim DE, Ha SW, Sohn SI, Kwon SU. The impact of prior antithrombotic status on cerebral infarction in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014 Sep;23(8):2054-2059. doi: 10.1016/j.jstrokecerebrovasdis.2014.03.011. Epub 2014 Aug 10.</citation>
    <PMID>25113085</PMID>
  </reference>
  <reference>
    <citation>Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.</citation>
    <PMID>19717844</PMID>
  </reference>
  <reference>
    <citation>Kim BJ, Kang HG, Lee DH, Kang DW, Kim JS, Kwon SU. Ischemic stroke on optimal anticoagulation with novel-oral anticoagulants compared with warfarin. Int J Stroke. 2015 Aug;10(6):E68. doi: 10.1111/ijs.12587.</citation>
    <PMID>26202718</PMID>
  </reference>
  <reference>
    <citation>Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.</citation>
    <PMID>24251359</PMID>
  </reference>
  <reference>
    <citation>Pérez-Gómez F, Alegría E, Berjón J, Iriarte JA, Zumalde J, Salvador A, Mataix L; NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol. 2004 Oct 19;44(8):1557-66.</citation>
    <PMID>15489085</PMID>
  </reference>
  <reference>
    <citation>Ois A, Cuadrado-Godia E, Rodríguez-Campello A, Giralt-Steinhauer E, Jiménez-Conde J, Lopez-Cuiña M, Ley M, Soriano C, Roquer J. Relevance of stroke subtype in vascular risk prediction. Neurology. 2013 Aug 6;81(6):575-80. doi: 10.1212/WNL.0b013e31829e6f37. Epub 2013 Jul 3.</citation>
    <PMID>23825174</PMID>
  </reference>
  <reference>
    <citation>Kang K, Park TH, Kim N, Jang MU, Park SS, Park JM, Ko Y, Lee S, Lee KB, Lee J, Kim DE, Cho YJ, Kim JT, Kim DH, Cha JK, Han MK, Lee JS, Lee J, Oh MS, Choi JC, Lee BC, Hong KS, Bae HJ. Recurrent Stroke, Myocardial Infarction, and Major Vascular Events during the First Year after Acute Ischemic Stroke: The Multicenter Prospective Observational Study about Recurrence and Its Determinants after Acute Ischemic Stroke I. J Stroke Cerebrovasc Dis. 2016 Mar;25(3):656-64. doi: 10.1016/j.jstrokecerebrovasdis.2015.11.036. Epub 2015 Dec 29.</citation>
    <PMID>26750575</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Sun U. Kwon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

